Abstract
Human mast cells (HMC-1) take up anandamide (arachidonoyl-ethanolamide, AEA) with a saturable process (K(m)=200+/-20 nM, V(max)=25+/-3 pmol min(-1) mg protein(-1)), enhanced two-fold over control by nitric oxide-donors. Internalized AEA was hydrolyzed by a fatty acid amide hydrolase (FAAH), whose activity became measurable only in the presence of 5-lipoxygenase, but not cyclooxygenase, inhibitors. FAAH (K(m)=5.0+/-0.5 microM, V(max)=160+/-15 pmol min(-1) mg protein(-1)) was competitively inhibited by palmitoylethanolamide. HMC-1 cells did not display a functional cannabinoid receptor on their surface and neither AEA nor palmitoylethanolamide affected tryptase release from these cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
5,8,11,14-Eicosatetraynoic Acid / pharmacology
-
Amides
-
Arachidonate 5-Lipoxygenase / metabolism*
-
Arachidonic Acids / pharmacokinetics*
-
Binding, Competitive
-
Biological Transport / drug effects
-
Cannabinoids / pharmacokinetics
-
Cell Line
-
Cyclooxygenase Inhibitors / pharmacology
-
Endocannabinoids
-
Ethanolamines
-
Humans
-
Ibuprofen / pharmacology
-
Indoles / pharmacology
-
Indomethacin / pharmacology
-
Kinetics
-
Lipoxygenase Inhibitors / pharmacology*
-
Mast Cells / metabolism*
-
Palmitic Acids / pharmacology
-
Polyunsaturated Alkamides
-
Receptors, Cannabinoid
-
Receptors, Drug / analysis
-
Tritium
Substances
-
Amides
-
Arachidonic Acids
-
Cannabinoids
-
Cyclooxygenase Inhibitors
-
Endocannabinoids
-
Ethanolamines
-
Indoles
-
Lipoxygenase Inhibitors
-
Palmitic Acids
-
Polyunsaturated Alkamides
-
Receptors, Cannabinoid
-
Receptors, Drug
-
MK-886
-
Tritium
-
5,8,11,14-Eicosatetraynoic Acid
-
palmidrol
-
Arachidonate 5-Lipoxygenase
-
anandamide
-
Ibuprofen
-
Indomethacin